Back to News & Events

DRIVe Special Instructions & EZ-BAA Updates

Two important updates regarding upcoming BARDA DRIVe funding opportunities: 

Drive Special Instructions – Due May 28!
White papers, quad chart, and application form for the DRIVe special instructions to the BARDA BAA are due by 3:00 PM ET on Tuesday May 28th, 2019.
Focus areas are:
• 15.1: Advanced Research and Development of Sepsis Diagnostics and Devices
• 15.2: Post-sepsis Monitoring
• 16.1: On-Person, Wearable, and Biosensing Devices (Host Response and Direct Pathogen Detection)

Steps to apply:
1.Review Solicitation BAA-18-100-SOL-00003 on fbo.gov.
2.Schedule a meeting with the ENACT or Solving Sepsis team (strongly encouraged).
3.Download the DRIVe Special Instructions Submission Form.*
4.Complete the PDF form, Quad Chart, White Paper, and Addendum (ROM cost estimate).
5. Email your submission to DRIVeContracting@hhs.gov by 3:00PM ET on May 28th.
6. You will receive an email notification confirming receipt within 5 business days. DRIVe personnel will review your white paper as described in the solicitation.
7. DRIVe personnel will notify you of the outcome of that review and may invite you to submit a full proposal.
*You must download the PDF, as filling it out in a browser window will disable some key functionality.

General DRIVe EZ-BAA – Deadline Extended 
The deadline for DRIVe’s EZ-BAA has been extended to 3:00 PM ET on November 15th, 2019. Applications are reviewed on a rolling basis with a response as early as 30 days after submission.

DRIVe has a new online portal for submitting EZ-BAA. Note: Companies must register for a profile in the online portal here, it can take up to 1 business day to account to be created.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 5065
                    [post_author] => 4
                    [post_date] => 2026-09-01 14:03:32
                    [post_date_gmt] => 2026-09-01 18:03:32
                    [post_content] => 

Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.

BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.

Application deadline: October 29, 2026, 5:00pm ET

For info sessions, eligibility and deadlines visit our REACH Website and FAQ.

The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.

Questions? Reach out to our program contacts or sign up for office hours:

Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here

Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here

[post_title] => BioREACH: Translational Research Funding Opportunity [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bioreach-translational-research-funding-opportunity [to_ping] => [pinged] => [post_modified] => 2026-09-04 11:55:36 [post_modified_gmt] => 2026-09-04 15:55:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5065 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2971 [post_author] => 4 [post_date] => 2018-05-15 15:18:07 [post_date_gmt] => 2018-05-15 15:18:07 [post_content] => The Long Island BioMentor Initiative (LIBMI) officially accepted its first program applications in a “launch event” at the de Seversky Mansion on Thursday May 10, 2018. Already a year into a “pilot phase,” the LIBMI was developed in league with the Massachusetts Institute of Technology’s Venture Mentoring Service which employs an “objective team-mentoring model” for early-stage businesses that champions one strict rule above all others: The uber-qualified mentors are prohibited from investing in, pitching business to or otherwise profiting from their mentees. Read the full article from Innovate Long Island. [post_title] => “Heavy-Hitting LI BioMentor Initiative Makes It Official” [post_excerpt] => The Long Island BioMentor Initiate (LIBMI) officially “launches” at an event held at the de Seversky Mansion on Thursday May 10, 2018. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => heavy-hitting-li-biomentor-initiative-makes-it-official [to_ping] => [pinged] => [post_modified] => 2019-01-25 14:48:57 [post_modified_gmt] => 2019-01-25 14:48:57 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2971 [menu_order] => 122 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2253 [post_author] => 3 [post_date] => 2016-06-16 16:15:26 [post_date_gmt] => 2016-06-16 16:15:26 [post_content] => regenix_web1Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing led by Novo A/S and Sofinnova Partners, with participation from existing investors including Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP. The financing will support clinical development of Rgenix’s lead drug candidates, RGX-104 and RGX-202, as well as further development of its therapeutics pipeline. In connection with the financing, Nilesh Kumar of Novo Ventures and Antoine Papiernik of Sofinnova Partners will join the Rgenix Board of Directors together with existing members, including Executive Chairman Eric Rowinsky, M.D., Masoud Tavazoie, M.D. Ph.D., Nancy Chang, Ph.D., and Saeed Tavazoie, Ph.D. Read the full press release about Rgenix’s financing here. [post_title] => Rgenix Announces $33M Series B Financing [post_excerpt] => Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing led by Novo A/S and Sofinnova Partners, with participation from existing investors including Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP. The financing will support clinical development of Rgenix’s lead drug candidates, RGX-104 and RGX-202, as well as further development of its therapeutics pipeline. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => rgenix-announces-33m-series-b-financing [to_ping] => [pinged] => [post_modified] => 2016-06-16 16:17:16 [post_modified_gmt] => 2016-06-16 16:17:16 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2253 [menu_order] => 176 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 1475 [post_author] => 3 [post_date] => 2015-03-26 16:37:02 [post_date_gmt] => 2015-03-26 16:37:02 [post_content] => Eavesdropping on Investors' Closed Door Discussions" 1st Pitch Life Sciences Meeting Tuesday, April 14, 2015 5:30pm - 8:30pm Hear what happens after a start-up company presents to an investor group. Usually after the company representatives leave the room the investors have a private discussion to decide whether the opportunity merits further investigation and possible investment. 1st Pitch Life Science offers presenters and audience members the chance to hear what happens in those closed-door discussion, and to learn what really matters to investors. 1st Pitch Life Science is organized by MABA (Mid Atlantic Bio Angels www.bioangels.net), a life science investor group, to encourage and educate aspiring life science entrepreneurs who know they may be too early or not fully prepared to seek investment but want the opportunity to practice their pitch and to receive constructive criticism from experienced and knowledgeable professionals. To Register: https://1stpitchapril2015.eventbrite.com When: Tuesday, April 14th, 2015 5:30pm : Registration & Networking 6:00 - 8:00pm : Program 8:00 - 8:30pm : Networking Where:** Please note new location** New York Genome Center 101 Avenue of the Americas New York, NY 10013   [post_title] => 1st Pitch Life Sciences Meeting - April 14 [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => 1st-pitch-life-sciences-meeting-april-14 [to_ping] => [pinged] => [post_modified] => 2016-03-02 18:13:17 [post_modified_gmt] => 2016-03-02 18:13:17 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1475 [menu_order] => 207 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 5065 [post_author] => 4 [post_date] => 2026-09-01 14:03:32 [post_date_gmt] => 2026-09-01 18:03:32 [post_content] =>

Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.

BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.

Application deadline: October 29, 2026, 5:00pm ET

For info sessions, eligibility and deadlines visit our REACH Website and FAQ.

The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.

Questions? Reach out to our program contacts or sign up for office hours:

Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here

Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here

[post_title] => BioREACH: Translational Research Funding Opportunity [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bioreach-translational-research-funding-opportunity [to_ping] => [pinged] => [post_modified] => 2026-09-04 11:55:36 [post_modified_gmt] => 2026-09-04 15:55:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5065 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 285 [max_num_pages] => 95 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

BioREACH: Translational Research Funding Opportunity

More Information

“Heavy-Hitting LI BioMentor Initiative Makes It Official”

More Information

Rgenix Announces $33M Series B Financing

More Information

1st Pitch Life Sciences Meeting – April 14

More Information